Artal Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-936
| Closed | -$166K | – | 98 |
|
|
2023
Q3 | $166K | Hold |
936
| – | – | 0.01% | 97 |
|
|
2023
Q2 | $178K | Buy |
+936
| New | +$186K | 0.01% | 114 |
|
|
2022
Q3 | – | Sell |
-600,000
| Closed | -$87.5M | – | 137 |
|
|
2022
Q2 | $87.5M | Sell |
600,000
-50,000
| -8% | -$7.09M | 4.67% | 6 |
|
|
2022
Q1 | $106M | Hold |
650,000
| – | – | 4.44% | 6 |
|
|
2021
Q4 | $110M | Sell |
650,000
-50,000
| -7% | -$9.29M | 2.99% | 7 |
|
|
2021
Q3 | $132M | Sell |
700,000
-50,000
| -7% | -$9.38M | 2.96% | 9 |
|
|
2021
Q2 | $127M | Hold |
750,000
| – | – | 2.58% | 9 |
|
|
2021
Q1 | $106M | Sell |
750,000
-50,000
| -6% | -$7.52M | 1.87% | 13 |
|
|
2020
Q4 | $104M | Hold |
800,000
| – | – | 2.23% | 9 |
|
|
2020
Q3 | $116M | Sell |
800,000
-100,000
| -11% | -$14.2M | 2.83% | 8 |
|
|
2020
Q2 | $133M | Sell |
900,000
-200,000
| -18% | -$27M | 3.73% | 6 |
|
|
2020
Q1 | $120M | Buy |
1,100,000
+100,000
| +10% | +$11.5M | 5.06% | 4 |
|
|
2019
Q4 | $115M | Buy |
1,000,000
+300,000
| +43% | +$29.9M | 4.45% | 3 |
|
|
2019
Q3 | $56.3M | Buy |
700,000
+300,000
| +75% | +$23.7M | 2.26% | 12 |
|
|
2019
Q2 | $29M | Sell |
400,000
-50,000
| -11% | -$3.84M | 1.17% | 21 |
|
|
2019
Q1 | $42.1M | Sell |
450,000
-50,000
| -10% | -$4.18M | 1.72% | 16 |
|
|
2018
Q4 | $36.5M | Sell |
500,000
-100,000
| -17% | -$7.69M | 1.35% | 15 |
|
|
2018
Q3 | $52.5M | Sell |
600,000
-50,000
| -8% | -$5.03M | 1.37% | 13 |
|
|
2018
Q2 | $64M | Buy |
650,000
+50,000
| +8% | +$4.96M | 1.36% | 9 |
|
|
2018
Q1 | $71.5M | Buy |
600,000
+150,000
| +33% | +$19.3M | 0.89% | 12 |
|
|
2017
Q4 | $57.2M | Buy |
450,000
+200,000
| +80% | +$25.1M | 0.86% | 11 |
|
|
2017
Q3 | $29.4M | Sell |
250,000
-25,000
| -9% | -$2.13M | 0.51% | 12 |
|
|
2017
Q2 | $21.9M | Sell |
275,000
-25,000
| -8% | -$1.6M | 0.38% | 24 |
|
|
2017
Q1 | $15.4M | Sell |
300,000
-200,000
| -40% | -$9.24M | 0.34% | 27 |
|
|
2016
Q4 | $18.7M | Sell |
500,000
-100,000
| -17% | -$4.19M | 0.42% | 24 |
|
|
2016
Q3 | $40.7M | Sell |
600,000
-110,000
| -15% | -$7.76M | 0.81% | 10 |
|
|
2016
Q2 | $39.4M | Buy |
710,000
+110,000
| +18% | +$6.93M | 0.81% | 8 |
|
|
2016
Q1 | $37.7M | Buy |
600,000
+125,000
| +26% | +$8.31M | 0.73% | 9 |
|
|
2015
Q4 | $44.7M | Buy |
475,000
+40,000
| +9% | +$3.71M | 0.84% | 14 |
|
|
2015
Q3 | $35M | Sell |
435,000
-20,000
| -4% | -$2.22M | 0.78% | 15 |
|
|
2015
Q2 | $54.5M | Sell |
455,000
-15,000
| -3% | -$1.79M | 2.35% | 9 |
|
|
2015
Q1 | $49.1M | Buy |
470,000
+70,000
| +18% | +$7.09M | 2.27% | 12 |
|
|
2014
Q4 | $38.8M | Buy |
400,000
+100,000
| +33% | +$9.26M | 1.36% | 13 |
|
|
2014
Q3 | $23.4M | Hold |
300,000
| – | – | 0.86% | 24 |
|
|
2014
Q2 | $19M | Buy |
300,000
+95,000
| +46% | +$5.65M | 0.77% | 28 |
|
|
2014
Q1 | $13.8M | Buy |
205,000
+80,000
| +64% | +$6.19M | 0.5% | 44 |
|
|
2013
Q4 | $8.04M | Buy |
+125,000
| New | +$7.46M | 0.29% | 50 |
|
Other funds holding ALNY
Artal Group's ALNY Position: Q4 2023 in Review
Artal Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 936 shares — an estimated $166K sold.
Artal Group first reported a position in ALNY in Q4 2013 and held it in 37 quarters. The position peaked at $133M in Q2 2020. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.
- Artal Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
- Artal Group sold 936 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $166K.
- Artal Group first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 37 quarters.
- Artal Group's Alnylam Pharmaceuticals position peaked at $133M in Q2 2020.
- 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.
Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.